当前位置: 首页 >> 检索结果
461. A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.
作者: Jolene Kay Berg.;Eric H Kim.;Benjamin Li.;Bo Joelsson.;Nader N Youssef.
来源: BMC Gastroenterol. 2014年14卷25页
Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recently approved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with some studies showing no effect and others documenting a GLP-2-dependent delay in gastric emptying. The primary objective of this study was to assess the effect of teduglutide on gastric emptying of liquids in healthy subjects, as measured by the pharmacokinetics of acetaminophen.
462. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
作者: Remo Panaccione.;Subrata Ghosh.;Stephen Middleton.;Juan R Márquez.;Boyd B Scott.;Laurence Flint.;Hubert J F van Hoogstraten.;Annie C Chen.;Hanzhe Zheng.;Silvio Danese.;Paul Rutgeerts.
来源: Gastroenterology. 2014年146卷2期392-400.e3页
The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previously.
463. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
作者: Henry L Y Chan.;Chi Kuen Chan.;Aric Josun Hui.;Sing Chan.;Fred Poordad.;Ting-Tsung Chang.;Philippe Mathurin.;John F Flaherty.;Lanjia Lin.;Amy Corsa.;Anuj Gaggar.;G Mani Subramanian.;John G McHutchison.;George Lau.;Sam Lee.;Edward J Gane.
来源: Gastroenterology. 2014年146卷5期1240-8页
Little is known about the benefit of antiviral therapy for hepatitis B e antigen (HBeAg)-positive patients with high viral load and normal levels of alanine aminotransferase. We evaluated the effects of single and combination therapies in immune-tolerant patients with chronic hepatitis B.
464. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
作者: Stephan Miehlke.;Ahmed Madisch.;Limas Kupcinskas.;Dalius Petrauskas.;Günter Böhm.;Hans-Joachim Marks.;Michael Neumeyer.;Torben Nathan.;Fernando Fernández-Bañares.;Roland Greinwald.;Ralf Mohrbacher.;Michael Vieth.;Ole K Bonderup.; .
来源: Gastroenterology. 2014年146卷5期1222-30.e1-2页
Studies reporting that budesonide is effective for the treatment of collagenous colitis have been small and differed in efficacy measures. Mesalamine has been proposed as a treatment option for collagenous colitis, although its efficacy has never been investigated in placebo-controlled trials. We performed a phase 3, placebo-controlled, multicenter study to evaluate budesonide and mesalamine as short-term treatments for collagenous colitis.
465. High dose multiple micronutrient supplementation improves villous morphology in environmental enteropathy without HIV enteropathy: results from a double-blind randomised placebo controlled trial in Zambian adults.
作者: John Louis-Auguste.;Stephen Greenwald.;Michelo Simuyandi.;Rose Soko.;Rose Banda.;Paul Kelly.
来源: BMC Gastroenterol. 2014年14卷15页
Environmental enteropathy (EE) is an asymptomatic abnormality of small bowel structure and function, which may underlie vaccine inefficacy in the developing world. HIV infection co-exists in many of these populations. There is currently no effective treatment. We conducted a secondary analysis of a randomised controlled trial of high dose multiple micronutrient (MM) supplementation on small bowel architecture in EE in participants with or without HIV infection.
466. Detection of drug effects on gastric emptying and contractility using a wireless motility capsule.
作者: Inna Rozov-Ung.;Amjad Mreyoud.;John Moore.;Gregory E Wilding.;Elias Khawam.;Jeffrey M Lackner.;John R Semler.;Michael D Sitrin.
来源: BMC Gastroenterol. 2014年14卷2页
A wireless motility capsule is a new method for ambulatory assessment of transit times and motility throughout the gastrointestinal tract. The objective of this study was to evaluate the ability of a wireless motility capsule to detect drug effects on gastric emptying time (GET) and gastric contractility.
467. Safety and effectiveness using dexmedetomidine versus propofol TCI sedation during oesophagus interventions: a randomized trial.
作者: Susanne Eberl.;Benedikt Preckel.;Jacques J Bergman.;Markus W Hollmann.
来源: BMC Gastroenterol. 2013年13卷176页
Endoscopic treatment of early neoplastic lesions in oesophagus has evolved as a valid and less invasive alternative to surgical resection. These endoscopic interventions are minimal invasive treatment options usually done with sedation on an outpatient basis. The aim of this trial is to determine the safety and effectiveness of dexmedetomidine sedation compared to the standard used propofol TCI sedation during endoscopic oesophageal interventions.
468. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
作者: Scott Fung.;Peter Kwan.;Milotka Fabri.;Andrzej Horban.;Mijomir Pelemis.;Hie-Won Hann.;Selim Gurel.;Florin A Caruntu.;John F Flaherty.;Benedetta Massetto.;Phillip Dinh.;Amoreena Corsa.;G Mani Subramanian.;John G McHutchison.;Petr Husa.;Edward Gane.
来源: Gastroenterology. 2014年146卷4期980-8页
Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited.
469. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
作者: Maria Buti.;Kosh Agarwal.;Yves Horsmans.;William Sievert.;Ewa Janczewska.;Stefan Zeuzem.;Lisa Nyberg.;Robert S Brown.;Christophe Hézode.;Mario Rizzetto.;Raymundo Paraná.;Sandra De Meyer.;Ralph De Masi.;Donghan Luo.;Kirk Bertelsen.;James Witek.
来源: Gastroenterology. 2014年146卷3期744-753.e3页
We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.
470. Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): design and rationale of a randomised controlled multicenter trial [ISRCTN09186711].
作者: Sandra van Brunschot.;Janneke van Grinsven.;Rogier P Voermans.;Olaf J Bakker.;Marc G H Besselink.;Marja A Boermeester.;Thomas L Bollen.;Koop Bosscha.;Stefan A Bouwense.;Marco J Bruno.;Vincent C Cappendijk.;Esther C Consten.;Cornelis H Dejong.;Marcel G W Dijkgraaf.;Casper H van Eijck.;G Willemien Erkelens.;Harry van Goor.;Mohammed Hadithi.;Jan-Willem Haveman.;Sijbrand H Hofker.;Jeroen J M Jansen.;Johan S Laméris.;Krijn P van Lienden.;Eric R Manusama.;Maarten A Meijssen.;Chris J Mulder.;Vincent B Nieuwenhuis.;Jan-Werner Poley.;Rogier J de Ridder.;Camiel Rosman.;Alexander F Schaapherder.;Joris J Scheepers.;Erik J Schoon.;Tom Seerden.;B W Marcel Spanier.;Jan Willem A Straathof.;Robin Timmer.;Niels G Venneman.;Frank P Vleggaar.;Ben J Witteman.;Hein G Gooszen.;Hjalmar C van Santvoort.;Paul Fockens.; .
来源: BMC Gastroenterol. 2013年13卷161页
Infected necrotising pancreatitis is a potentially lethal disease that nearly always requires intervention. Traditionally, primary open necrosectomy has been the treatment of choice. In recent years, the surgical step-up approach, consisting of percutaneous catheter drainage followed, if necessary, by (minimally invasive) surgical necrosectomy has become the standard of care. A promising minimally invasive alternative is the endoscopic transluminal step-up approach. This approach consists of endoscopic transluminal drainage followed, if necessary, by endoscopic transluminal necrosectomy. We hypothesise that the less invasive endoscopic step-up approach is superior to the surgical step-up approach in terms of clinical and economic outcomes.
471. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.
作者: Brian G Feagan.;John W D McDonald.;Remo Panaccione.;Robert A Enns.;Charles N Bernstein.;Terry P Ponich.;Raymond Bourdages.;Donald G Macintosh.;Chrystian Dallaire.;Albert Cohen.;Richard N Fedorak.;Pierre Paré.;Alain Bitton.;Fred Saibil.;Frank Anderson.;Allan Donner.;Cindy J Wong.;Guangyong Zou.;Margaret K Vandervoort.;Marybeth Hopkins.;Gordon R Greenberg.
来源: Gastroenterology. 2014年146卷3期681-688.e1页
Methotrexate and infliximab are effective therapies for Crohn's disease (CD). In the combination of maintenance methotrexate-infliximab trial, we evaluated the potential superiority of combination therapy over infliximab alone.
472. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
作者: Edward J Gane.;Catherine A Stedman.;Robert H Hyland.;Xiao Ding.;Evguenia Svarovskaia.;G Mani Subramanian.;William T Symonds.;John G McHutchison.;Phillip S Pang.
来源: Gastroenterology. 2014年146卷3期736-743.e1页
We evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS-9669 in patients with genotype 1 hepatitis C virus (HCV) infection.
473. Prediction of symptomatic improvement after exposure-based treatment for irritable bowel syndrome.
作者: Brjánn Ljótsson.;Erik Andersson.;Perjohan Lindfors.;Jeffrey M Lackner.;Karin Grönberg.;Katarina Molin.;Johanna Norén.;Karin Romberg.;Evelyn Andersson.;Timo Hursti.;Hugo Hesser.;Erik Hedman.
来源: BMC Gastroenterol. 2013年13卷160页
Several studies show that psychological treatments relieve symptoms for patients suffering from irritable bowel syndrome (IBS). However, there are no consistent findings that show what patient characteristics make a psychological treatment more or less likely to result in improvement. We have previously conducted a study of a newly developed internet-delivered cognitive behavioral therapy (ICBT) that emphasized exposure to IBS symptoms and IBS-related situations and reduced symptom-related avoidance. The study showed that the treatment led to improvement in IBS symptoms compared to a waiting list and that treatment gains were maintained over a 15-18 month follow-up period. The aim of the present study was to investigate several possible predictors of short- and long-term treatment outcome in terms of symptom improvement, based on data collected in the previously conducted treatment trial.
474. Comfort, safety and quality of upper gastrointestinal endoscopy after 2 hours fasting: a randomized controlled trial.
作者: Angélica Terezinha Koeppe.;Marcio Lubini.;Nilton Maiolini Bonadeo.;Iran Moraes.;Fernando Fornari.
来源: BMC Gastroenterol. 2013年13卷158页
Upper gastrointestinal endoscopy has been performed after fasting 8 or more hours, which can be harmful to the patients. We assessed comfort, safety and quality of endoscopy under moderate sedation after 2 hours fasting for clear liquids.
475. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
作者: Stefan Zeuzem.;Thomas Berg.;Edward Gane.;Peter Ferenci.;Graham R Foster.;Michael W Fried.;Christophe Hezode.;Gideon M Hirschfield.;Ira Jacobson.;Igor Nikitin.;Paul J Pockros.;Fred Poordad.;Jane Scott.;Oliver Lenz.;Monika Peeters.;Vanitha Sekar.;Goedele De Smedt.;Rekha Sinha.;Maria Beumont-Mauviel.
来源: Gastroenterology. 2014年146卷2期430-41.e6页
Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection. We performed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon-α2a (PegIFN), and ribavirin (RBV) in patients with HCV genotype-1 infection previously treated with PegIFN and RBV.
476. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
作者: Gregory T Everson.;Karen D Sims.;Maribel Rodriguez-Torres.;Christophe Hézode.;Eric Lawitz.;Marc Bourlière.;Veronique Loustaud-Ratti.;Vinod Rustgi.;Howard Schwartz.;Harvey Tatum.;Patrick Marcellin.;Stanislas Pol.;Paul J Thuluvath.;Timothy Eley.;Xiaodong Wang.;Shu-Pang Huang.;Fiona McPhee.;Megan Wind-Rotolo.;Ellen Chung.;Claudio Pasquinelli.;Dennis M Grasela.;David F Gardiner.
来源: Gastroenterology. 2014年146卷2期420-9页
The combination of peginterferon and ribavirin with telaprevir or boceprevir is the standard treatment of hepatitis C virus (HCV) genotype 1 infection. However, these drugs are not well tolerated because of their side effects and suboptimal virologic responses. In a phase 2a, open-label study, we examined the safety and efficacy of an interferon-free, ribavirin-free regimen of direct-acting antivirals, comprising daclatasvir (an NS5A replication complex inhibitor), asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a non-nucleoside NS5B inhibitor), in patients with chronic HCV infection.
477. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
作者: Nezam H Afdhal.;Geoffrey M Dusheiko.;Edoardo G Giannini.;Pei-Jer Chen.;Kwang-Hyub Han.;Aftab Mohsin.;Maribel Rodriguez-Torres.;Sorin Rugina.;Igor Bakulin.;Eric Lawitz.;Mitchell L Shiffman.;Ghias-Un-Nabi Tayyab.;Fred Poordad.;Yasser Mostafa Kamel.;Andres Brainsky.;James Geib.;Sandra Y Vasey.;Rita Patwardhan.;Fiona M Campbell.;Dickens Theodore.
来源: Gastroenterology. 2014年146卷2期442-52.e1页
Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV.
478. Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
作者: Hubert Mönnikes.;Thomas Schwan.;Christo van Rensburg.;Andrzej Straszak.;Carmen Theek.;Reinhold Lühmann.;Peter Sander.;Anne Tholen.
来源: BMC Gastroenterol. 2013年13卷145页
Symptoms suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with those of gastroesophageal reflux disease. Despite the high prevalence of symptomatic overlap, the underlying etiology remains poorly defined. We assessed the correlation of symptomatic relief and health-related quality of life (HRQoL) with healing of reflux esophagitis to further derive insights into the underlying etiology.
479. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
作者: Emma P Halmos.;Victoria A Power.;Susan J Shepherd.;Peter R Gibson.;Jane G Muir.
来源: Gastroenterology. 2014年146卷1期67-75.e5页
A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) often is used to manage functional gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evidence of its efficacy, compared with a normal Western diet. We investigated the effects of a diet low in FODMAPs compared with an Australian diet, in a randomized, controlled, single-blind, cross-over trial of patients with IBS.
480. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
作者: Brian G Feagan.;William J Sandborn.;Andreas Lazar.;Roopal B Thakkar.;Bidan Huang.;Nattanan Reilly.;Naijun Chen.;Mei Yang.;Martha Skup.;Parvez Mulani.;Jingdong Chao.
来源: Gastroenterology. 2014年146卷1期110-118.e3页
Adalimumab is effective for induction and maintenance of remission in patients with moderate to severe ulcerative colitis (UC). We assessed whether adalimumab, in addition to standard UC therapy, reduced the risk for hospitalization (from all causes, from complications of UC, or from complications of UC or the drugs used to treat it) and colectomy in patients with moderate to severe UC compared with placebo.
|